Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Enterin

Enterin
2014 FOUNDED
PRIVATE STATUS
Series B LATEST DEAL TYPE
$16.7M LATEST DEAL AMOUNT
2 INVESTORS
Description

Developer of novel drugs intended to repair the dysfunctional gut-brain axis. The company's drugs displaces α-synuclein aggregates and restores normal signaling between the gut and the brain, enabling patients with Parkinson's disease and other neurodegenerative conditions to have a better the quality of life.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Primary Office
  • 2005 Market Street
  • Suite 3125
  • Philadelphia, PA 19103
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Enterin’s full profile, request a free trial.

Enterin Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series B) 28-Jan-2019 $16.7M 000.00 00000 Completed Clinical Trials - Phase 2
2. Early Stage VC (Series A2) 10-Jul-2017 000.00 000.00 000.00 Completed Clinical Trials - Phase 1
1. Accelerator/Incubator Completed Clinical Trials - Phase 1
To view this company’s complete deal history including valuation and funding, request access »

Enterin Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B 0,000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series A-2 0,000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series A-1 2,846,620 $0.000100 5% $2.91 $2.91 1x $2.91 12.23%
To view this company’s complete Cap Table, request access »

Enterin Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
New Ventures Funds Venture Capital Minority 000 0000 000000 0
Science Center Accelerator/Incubator 000 0000 000000 0

Enterin Executive Team (4)

Name Title Board
Seat
Contact
Info
Michael Zasloff Ph.D Co-Founder, Chairman & Chief Executive Officer
Nancy Ness Chief Financial Officer
Denise Barbut MD Co-Founder, President, Chief Medical Officer & Board Member
William Kinney Ph.D Co-Founder & Senior Vice President, Research & Development

Enterin Board Members (4)

Name Representing Role Since Contact
Info
Jay Brammer Enterin Board Member 000 0000
Mark Finn New Ventures Funds Board Member 000 0000
Michael Zasloff Ph.D Enterin Co-Founder, Chairman & Chief Executive Officer 000 0000
Richard Propper MD Enterin Board Member 000 0000